Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5639_Библиотеки_им_академика_М_И_Перельмана
.pdf
402
https://t.me/med1917
algorithms can learn from these data and make predictions about the properties
or activities of novel compounds. Additionally, they can recommend new compounds or chemical modications to enhance the desired biological activity. AI
can also optimize the HTS process itself by assisting in experiment design and
helping researchers choose the most relevant compounds for screening. It can
automate data analysis and decision-making steps, reducing human error and
increasing efciency. AI-powered robotics and automation systems can manage
complex tasks such as compound handling, assay setup, and data recording,
allowing high-throughput screening to be conducted at an unparalleled scale.
The integration of AI with HTS and automation has accelerated the drug discovery process, allowing researchers to screen a vast chemical space and identify
potential drug candidates more efciently. It has also led to the discovery of
novel compounds and targets that may have been overlooked using traditional
methods. As AI continues to advance, it holds tremendous potential in enhancing the speed and precision of high-throughput screening (HTS) and automation, ultimately contributing to the identication of novel drugs and therapeutic
strategies.
K. Nailwal et al.
18.7 Molecular Design andOptimization
Molecular design and optimization for drug discovery and development are a
meticulous and transformative process. It begins with the identication of key
biological targets, such as proteins or receptors, pivotal in disease pathways,
which serve as the foundation for therapeutic interventions. Researchers then
embark on the journey of identifying small molecules, or “hits,” through
advanced techniques such as high- throughput screening and virtual screening,
ultimately seeking compounds that bind to the target and exhibit promising initial activities. Conventional approaches for molecular design and optimization
have generally involved slow, expensive, and arduous trial-and-error experimental efforts. The biggest challenge for researchers was determining the most
viable compounds, uncovering intricate molecular interactions, and projecting
the safety and efciency of novel chemicals. The integration of articial intelligence (AI) and machine learning (ML) techniques has indeed revolutionized
the eld of molecular design and optimization. These advanced technologies
have signicantly expedited the process of designing and ne-tuning molecules
for various applications, such as drug discovery and materials science (Karaglani
et al. 2022; Karthikeyan and Priyakumar 2021; Fuhr and Sumpter 2022). In
recent years, articial intelligence (AI) and machine learning (ML) have gained
widespread adoption to accelerate molecular design across various elds,
including drug discovery and development. These cutting-edge technologies
have shown remarkable potential for enhancing high-throughput virtual screening and implementing global optimization methods for inverse design of materials (Selvaraj etal. 2021). AI-driven predictive models have greatly beneted the
18 AI: Catalyst forDrug Discovery andDevelopment
https://t.me/med1917
403
eld by accurately forecasting molecular properties, behaviors, and interactions. This aids in the selection of candidate molecules with the most promising
characteristics, reducing the need for extensive and costly laboratory experiments. Rational drug design has also been empowered by AI and ML.Researchers
can now use these technologies to design molecules that specically target disease-related proteins or biological pathways. This targeted approach enhances
the effectiveness of drug candidates and minimizes side effects, improving
patient outcomes (Brown etal. 2020). Beyond pharmaceuticals, AI and ML are
instrumental in discovering novel materials with unique properties. In elds
such as materials science, where the design of advanced materials for electronics, energy storage, or environmental applications is paramount, AI and ML
algorithms can help identify materials with desired characteristics. AI algorithms can also optimize chemical reactions, leading to increased yields and
reduced waste. This is not only environmentally responsible but also costeffective in industries such as chemical manufacturing. By ne-tuning reaction
conditions and parameters, AI can help create more efcient and sustainable
processes. Furthermore, machine learning models can adapt and improve in real
time as new data become available (Karaglani etal. 2022). This iterative process
ensures that the molecular design and optimization methods continually evolve
and become more accurate. In conclusion, the integration of AI and ML techniques has revolutionized molecular design and optimization. These technologies have enabled efcient exploration of chemical space, predictive modeling,
rational drug design, material discovery, optimization of chemical reactions,
and real-time learning. With the help of AI and ML, researchers can accelerate
the discovery and design process, leading to the development of more effective
drugs and advanced materials (Fig.18.9).
404
https://t.me/med1917
K. Nailwal et al.
Fig. 18.9 Generative models typically used in molecular generation: AE (a), VAE (b), and GAN
(c). (Karthikeyan and Priyakumar 2021)
18 AI: Catalyst forDrug Discovery andDevelopment
https://t.me/med1917
405
18.8 AI inClinical Trials
Clinical trials involve human volunteers participating in research studies to evaluate
the safety and effectiveness of new treatments, medications, or medical devices.
Clinical trials play a critical role in drug discovery by providing the evidence needed
to determine whether a drug is safe, effective, and appropriate for use in humans
(Araujo etal. 2020). Clinical trials are conducted in stages, with each stage serving
a different purpose in the drug development process. Phase I trials test the safety and
tolerance of the intervention in a subset of subjects, while phase II trials test efcacy
in a larger group. Phase III trials involve a large group of subjects and compare
interventions to existing treatments. Finally, once the intervention is approved, a
phase IV trial is conducted to evaluate long-term safety and efcacy. Bringing a new
drug to market is a lengthy and expensive process, taking an average of 10–15years
and costing around $1.5–2.0 billion. Clinical trials account for half of this time and
investment, while the other 50% covers preclinical compound discovery, testing,
and regulatory processes. Despite increased R&D investment from pharma and biotech companies, the number of new drugs approved per billion dollars spent has
decreased by half every 9years. With the drug discovery and development process
getting overly complex and difcult, there has been a growing interest in using articial intelligence (AI) in clinical trials (Scannell etal. 2012). AI has stepped into all
phases of the clinical trial cycle. Many pharmaceutical manufacturers have been
leveraging AI for multiple reasons, which are given in the following sections.
18.8.1 Faster andMore Efcient Patient Recruitment
AI can be used to identify the potential trial participants based on demographics,
medical history, and other criteria, enabling companies to recruit patients more
quickly and efciently. Several machine learning models based on natural language
processing, deep learning, and rule-based techniques have been deployed to achieve
this. NLP can analyze electronic health records (EHRs) and other clinical documents
to identify patients who meet specic criteria for a trial (Kersloot etal. 2020). Deep
learning algorithms can be deployed to analyze the medical imagery and genome
dataset to identify eligible patients. Much simpler ML techniques such as random
forests nd utility in nding suitable volunteers by building rule-based systems.
18.8.2 Patient Stratication
Patient stratication is an important aspect of clinical trials that allows us to ensure
diversity and representation of the patient population. It helps identify patient subgroups that may respond differently to the treatment being tested and minimizes the
406
https://t.me/med1917
risk of adverse events. Stratication based on relevant characteristics ensures meaningful and applicable trial results. AI can help identify patient subgroups based on
genetic, environmental, and other factors, enabling researchers to tailor treatments
for specic patient populations.
K. Nailwal et al.
18.8.3 Improved Trial Design
AI can be used in trial design with its capability to analyze large amounts of patient
data accurately and quickly, identify patterns for improved trial design and decisionmaking, and determine the best patient population, optimal treatment dosage, and
potential safety concerns. AI can also create predictive models to estimate trial success probabilities, identify problems beforehand, and identify potential biomarkers
for personalized treatment plans (Harrer etal. 2019). The use of AI in trial design
can improve clinical trial efciency and accuracy and ultimately lead to faster drug
development and better patient outcomes.
18.8.4 Real-Time Monitoring
Monitoring patient safety and efcacy data in real time is a crucial aspect of clinical
trials. It enables researchers to collect and analyze patient data continuously and
make informed decisions about various trial parameters. Real-time monitoring of
patient data includes tracking patient safety and efcacy outcomes, assessing
adverse events, and monitoring treatment dosages. By collecting patient data in real
time, researchers can identify potential safety issues early on and take appropriate
measures to mitigate risk. They can also adjust treatment dosages and management
strategies based on the data to ensure that patients receive the optimal treatment.
Additionally, real-time monitoring enables researchers to identify trends and patterns in patient data, which can help them make statistics-backed decisions about
trial design and protocol modications. Overall, real-time monitoring of patient
safety and efcacy data is critical for ensuring patient safety and the success of
clinical trials. By continuously monitoring patient data, researchers can optimize
trial outcomes, improve patient care, and provide valuable insights that can inform
future clinical research.
Now, we briey discuss the role AI plays in all the stages involved in clinical trial
(Shah etal. 2019):
Phase 1: AI holds signicant promise in improving the efciency and accuracy of
phase 1 clinical trials. By analyzing large quantities of patient data, AI algo-
rithms can identify potential safety concerns or adverse events more quickly and
accurately than traditional methods (Askin etal. 2023). Machine learning tech-
niques can also be used to optimize dosing and scheduling, helping to ensure that
18 AI: Catalyst forDrug Discovery andDevelopment
https://t.me/med1917
patients receive the correct amount of the drug for maximum effectiveness. This
can help speed up the drug development pipeline and cut the cost of involvement
in clinical trials.
Phase 2: AI has the potential to greatly enhance the efciency and accuracy of
phase 2 clinical trials. Advanced algorithms can be used to rapidly analyze large
volumes of patient data, identifying potential safety concerns or adverse events.
Machine learning techniques can also be utilized to optimize the dosing and
scheduling of the drug, allowing for more precise and effective treatment. As a
result, phase 2 trials can provide more detailed and reliable information about the
safety and efcacy of the drug. This information can then inform the design of
subsequent phase 3 trials, enabling more effective and targeted treatment options
for patients.
Phase 3: Phase 3 clinical trials are conducted with thousands of patients to evaluate
the safety and effectiveness of a new drug or treatment. They conrm the results
of earlier trials and provide more detailed information about the drug’s safety
and efcacy. Phase 3 trials are designed to reduce bias and ensure accuracy, and
the results are used to determine whether the drug can be approved by regulatory
agencies. AI can be used in clinical trials to handle and analyze large amounts of
data quickly and accurately, helping to speed up the drug development process.
Phase 4: Phase 4 clinical trials monitor the long-term safety and efcacy of drugs
in a larger patient population after regulatory approval. These trials involve thou-
sands of patients and may last for years, using a variety of study designs. The
results inform clinical practice guidelines and may identify new indications or
optimize dosing. Machine learning and AI analyze real-world data to identify
potential safety concerns, monitor drug effectiveness, and improve patient
outcomes.
407
18.9 Challenges andConsiderations
The integration of articial intelligence (AI) into drug development and design presents
an exciting frontier with the potential to revolutionize the pharmaceutical industry.
However, this transformative journey is not without its array of challenges and multifaceted considerations that demand a comprehensive approach to unlock AI’s full potential.
Foremost among these challenges is the need for vast and high- quality data. The complexity of drug development and the quest for precise predictions require AI models to
be built upon a foundation of extensive clinical and molecular information. Regrettably,
the limited availability of such data represents a signicant stumbling block, necessitating innovative solutions for data acquisition and management (Patel and Shah 2022).
Additionally, the “black box” nature of many AI algorithms poses an interpretability
conundrum. In the context of health care and drug development, transparency is paramount to engender trust. Consequently, there is a pressing need to develop AI models
that provide clear and intelligible explanations for their decisions, bridging the gap
between complex algorithms and human understanding. Addressing regulatory
408
https://t.me/med1917
compliance is another pivotal consideration. The absence of comprehensive guidelines
from esteemed agencies, such as the FDA, introduces uncertainty in establishing a clear
regulatory pathway for AI-driven drug discovery (Blanco-González et al. 2023).
Collaborative efforts between industry stakeholders and regulatory bodies are imperative to devise frameworks that accommodate the unique challenges and opportunities
presented by AI in drug development. Ethical concerns loom large in this landscape,
encompassing issues such as potential bias in AI algorithms and privacy. The establishment and adherence to rigorous ethical guidelines for data collection, model training,
and decision-making processes are vital to ensure the responsible and ethical development of AI models. The reproducibility and validation of AI models are indispensable in
establishing their reliability and generalizability. Fostering a culture of transparency and
open collaboration by rigorously validating procedures and openly sharing data and
code can signicantly contribute to achieving this goal. Simultaneously, the substantial
costs and resource intensity associated with building and maintaining AI systems must
be weighed against their potential benets and returns on investment. Exploring partnerships and collaborations and harnessing the capabilities of cloud-based services can alleviate the nancial burden tied to AI implementation. Integrating AI tools seamlessly
with existing drug development pipelines and methodologies represents another formidable challenge. Approaches for integrating AI-driven insights with existing workows
require prioritizing data security using encryption methods and strict access controls,
which guarantee the safeguarding of condential patients and research. Addressing the
shortage of AI and domain-specic experts in health care and life sciences is pivotal, and
it can be achieved through investments in training and education programs. Fostering
collaborations between AI experts and domain specialists fosters a synergy that accelerates innovation and problem-solving in the eld. Finally, establishing clear guidelines
for intellectual property rights and adapting existing legal frameworks to account for
AI-generated inventions are indispensable steps. This approach not only fosters innovation but also safeguards the rights of all parties involved, promoting a balanced and
conducive environment for advancement. In conclusion, the effective integration of AI
into drug development and design necessitates a holistic and multifaceted approach. It
encompasses addressing data quality, enhancing algorithm interpretability, navigating
regulatory compliance, mitigating ethical concerns, ensuring reproducibility, optimizing
cost-effectiveness, seamless integration with traditional methods, bolstering data security, fostering expertise, and establishing equitable guidelines for intellectual property
rights. By interweaving these diverse aspects, the potential of AI in drug development
can be maximized, propelling innovation and enhancing patient outcomes, leading to a
brighter and more promising future in health care.
K. Nailwal et al.
18.10 Conclusion
In this chapter, we have delved deeply into the inuence of articial intelligence on
the processes of drug discovery and development. It began with the recognition of
AI’s prominent role in the pharmaceutical industry, signaling a transformative era in
18 AI: Catalyst forDrug Discovery andDevelopment
https://t.me/med1917
409
the domain of drug development. It navigated through the various facets of AI’s
inuence; it became evident that machine learning, in particular, has emerged as a
powerful tool. It not only handles large datasets but also automates processes that
were historically labor-intensive and time-consuming. AI is not merely a technological advancement; it signies a fundamental shift in the approach to drug discovery. The integration of human expertise with AI algorithms has unlocked the
potential to unveil novel treatments concealed within the intricate complexity of
biological systems. Furthermore, it highlights the concrete advantages brought by
AI.It improves the precision of identifying potential drug targets, expedites the
decision-making processes related to promising drug candidates, and plays a pivotal
role in designing medicines with specic characteristics, ultimately enhancing their
effectiveness and safety proles. However, it is essential to acknowledge the challenges accompanying the integration of AI into drug discovery. These challenges
encompass concerns about data quality, the interpretability of AI-generated results,
and ethical considerations inherent to the use of AI in such a critical eld. In summary, this chapter unequivocally demonstrates AI’s central role as a catalyst for
transforming all aspects of drug discovery and development. As we conclude this
chapter, it becomes evident that AI holds the potential to revolutionize the pharmaceutical industry, promising the acceleration of life-saving drug development. While
challenges persist along the journey, the undeniable prospects of reshaping our
approach to drug development through AI should motivate researchers, practitioners, and all stakeholders to fully embrace this transformative change. By collectively embracing AI’s capabilities, we can expedite the discovery of new therapies,
ultimately leading to improved health outcomes for individuals around the world.
References
Ahn S, Lee SE, Kim M (2022) Random-forest model for drug–target interaction prediction via
Kullback–Leibler divergence. J Cheminform. https://doi.org/10.1186/s13321- 022- 00644- 1
Araujo MP, Al-Yaseen W, Innes NP (2020) A road map for designing and reporting clinical trials
in paediatric dentistry. Int J Paed Dent 31:14–22
Askin S, Burkhalter D, Calado G, El Dakrouni S (2023) Articial intelligence applied to clinical
trials: opportunities and challenges. Health Technol 13:203–213
Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro
Á, Garcia-Fandino R (2023) The role of AI in drug discovery: challenges, opportunities, and
strategies. Pharmaceuticals 16:891
Bodaghi A, Fattahi N, Ramazani A (2023) Biomarkers: promising and valuable tools towards diag-
nosis, prognosis and treatment of Covid-19 and other diseases. Heliyon 9:e13323
Brown N, Ertl P, Lewis R, Luksch T, Reker D, Schneider N (2020) Articial intelligence in chem-
istry and drug design. J Comput Aided Mol Des 34:709–715
Chen S, Li Z, Zhang S, Zhou Y, Xiao X, Cui P, Xu B, Zhao Q, Kong S, Dai Y (2022) Emerging bio-
technology applications in natural product and synthetic pharmaceutical analyses. Acta Pharm
Sin B 12:4075–4097
Daamen AR, Bachali P, Grammer AC, Lipsky PE (2023) Classication of COVID-19 patients into
clinically relevant subsets by a novel machine learning pipeline using transcriptomic features.
Int J Mol Sci 24:4905
410
https://t.me/med1917
Freund Y, Schapire RE (1997) A decision-theoretic generalization of on-line learning and an appli-
cation to boosting. J Comput Syst Sci 55:119–139
Fuhr AS, Sumpter BG (2022) Deep generative models for materials discovery and machine
learning- accelerated innovation. Front Mater 9:865270. https://doi.org/10.3389/
fmats.2022.865270
Han D, Mulyana B, Stankovic V, Cheng S (2023) A survey on deep reinforcement learning algo-
rithms for robotic manipulation. Sensors 23:3762
Harrer S, Shah P, Antony B, Hu J (2019) Articial intelligence for clinical trial design. Trends
Pharmacol Sci 40:577–591
Hathout RM, Metwally AA (2023) Tracing the nose-to-brain nanoparticulate drug delivery
using bio/chemoinformatics tools. In: A handbook of articial intelligence in drug delivery.
Academic Press, pp241–257
Heath JR, Ribas A, Mischel PS (2015) Single-cell analysis tools for drug discovery and develop-
ment. Nat Rev Drug Discov 15:204–216
Kapsiani S, Howlin BJ (2021) Random forest classication for predicting lifespan-extending
chemical compounds. Sci Rep 11:13812. https://doi.org/10.1038/s41598- 021- 93070- 6
Karaglani M, Panagopoulou M, Baltsavia I, Apalaki P, Theodosiou T, Iliopoulos I, Tsamardinos
I, Chatzaki E (2022) Tissue-specic methylation biosignatures for monitoring diseases: an in
silico approach. Int J Mol Sci 23:2959
Karthikeyan A, Priyakumar UD (2021) Articial intelligence: machine learning for chemical sci-
ences. J Chem Sci 134. https://doi.org/10.1007/s12039- 021- 01995- 2
Kersloot MG, van Putten FJP, Abu-Hanna A, Cornet R, Arts DL (2020) Natural language pro-
cessing algorithms for mapping clinical text fragments onto ontology concepts: a systematic
review and recommendations for future studies. J Biomed Semant. https://doi.org/10.1186/
s13326- 020- 00231- z
Kim J, Park S, Min D, Kim W (2021) Comprehensive survey of recent drug discovery using deep
learning. IJMS 22:9983
Kovács F, Legány C, Babos A (2005) Cluster validity measurement techniques. In: 6th International
symposium of Hungarian researchers on computational intelligence, p35
Liu S, See KC, Ngiam KY, Celi LA, Sun X, Feng M (2020) Reinforcement learning for clinical
decision support in critical care: comprehensive review. J Med Internet Res 22:e18477
McGinnis CS, Patterson DM, Winkler J etal (2019) MULTI-seq: sample multiplexing for single-
cell RNA sequencing using lipid-tagged indices. Nat Methods 16:619–626
Nasimian A, Al Ashiri L, Ahmed M, Duan H, Zhang X, Rönnstrand L, Kazi JU (2023) A receptor
tyrosine kinase inhibitor sensitivity prediction model identies AXL dependency in leukemia.
Int J Mol Sci 24:3830
Patel V, Shah M (2022) Articial intelligence and machine learning in drug discovery and develop-
ment. Intell Med 2(3):134–140
Popova M, Isayev O, Tropsha A (2018) Deep reinforcement learning for de novo drug design. Sci
Adv 4(7):eaap7885. https://doi.org/10.1126/sciadv.aap7885
Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, Heymach J, Le X, Yan H, Alam T (2023)
AI in drug discovery and its clinical relevance. Heliyon 9:e17575
Rokach L (2009) Using Fuzzy logic in data mining. In: Data mining and knowledge discovery
handbook. Springer, pp505–520
Sarkar C, Das B, Rawat VS, Wahlang JB, Nongpiur A, Tiewsoh I, Lyngdoh NM, Das D, Bidarolli
M, Sony HT (2023) Articial intelligence and machine learning technology driven modern
drug discovery and development. Int J Mol Sci 24:2026
Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceu-
tical R&D efciency. Nat Rev Drug Discov 11:191–200
Selvaraj C, Chandra I, Singh SK (2021) Articial intelligence and machine learning approaches
for drug design: challenges and opportunities for the pharmaceutical industries. Mol Divers
26:1893–1913
K. Nailwal et al.
18 AI: Catalyst forDrug Discovery andDevelopment
https://t.me/med1917
Shah P, Kendall F, Khozin S, Goosen R, Hu J, Laramie J, Ringel M, Schork N (2019) Articial
intelligence and machine learning in clinical development: a translational perspective. NPJ
Digit Med 2:69. https://doi.org/10.1038/s41746- 019- 0148- 3
Singh S, Kumar R, Payra S, Singh SK (2023) Articial intelligence and machine learning in phar-
macological research: bridging the gap between data and drug discovery. Cureus 15(8). https://
doi.org/10.7759/cureus.44359
Song Y-Y, Ying L (2015) Decision tree methods: applications for classication and prediction.
Shanghai Arch Psychiatry 27(2):130–135
Spitzer MH, Nolan GP (2016) Mass cytometry: single cells, many features. Cell 165:780–791
Takács G, Sándor M, Szalai Z, Kiss R, Balogh GT (2021) Analysis of the uncharted, druglike
property space by self-organizing maps. Mol Divers 26:2427–2441
Verikas A, Lipnickas A, Malmqvist K, Bacauskiene M, Gelzinis A (1999) Soft combination of
neural classiers: a comparative study. Pattern Recogn Lett 20:429–444
Vilar S, Costanzi S (2012) Predicting the biological activities through QSAR analysis and docking-
based scoring. Methods Mol Biol 914:271–284
Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP (2023) Articial intelligence
in pharmaceutical technology and drug delivery design. Pharmaceutics 15:1916
Zhang Y, Ye T, Xi H, Juhas M, Li J (2021) Deep learning driven drug discovery: tackling severe
acute respiratory syndrome coronavirus 2, vol 12. Front Microbiol, p739684
Zheng Q, Jiang Z, Ni X etal (2023) Machine learning quantied tumor-stroma ratio is an indepen-
dent prognosticator in muscle-invasive bladder cancer. Int J Mol Sci 24:2746
Zhou Z-H, Wu J, Tang W (2002) Ensembling neural networks: many could be better than all. Artif
Intell 137:239–263
411
Соседние файлы в папке Библиотека им академика М.И. Перельмана